Loading…
← Back to schedule
#112: Unintended Consequences: Effects of Inflation Reduction Act on the Future of Pharmaceutical Innovation
Monday June 16, 2025 11:00am - 12:00pm EDT
201
Component Type: Forum
Level: Intermediate
CE: ACPE 1.00 Knowledge UAN: 0286-0000-25-518-L04-P; CME 1.00; RN 1.00

Among the largest areas of concern with the Inflation Reduction Act (IRA) are potential unintended consequences to pharmaceutical innovation. This forum will convene industry experts to explore the impact of and potential adjustments to the IRA.

Learning Objectives

Discuss the unintended consequences of the IRA on innovation; Examine potential legislative solutions.

Chair

Sarah Martin, PhD, MS

Speaker

Panelist
Gregory Daniel, PhD, MPH

Industry Perspective
Ryan Gough

The Impacts of the Inflation Reduction Act on Biopharmaceutical Investment Decisions
Richard Xie, PhD

Early Signals of IRA Impact: Theoretical and Observed Unintended Consequences
Julie Ann Patterson, PharmD, PhD


Speakers
avatar for Gregory Daniel

Gregory Daniel

Global Head of Public Policy, Global Corporate Affairs, Eli Lilly and Company, United States
Gregory Daniel, PhD, MPH, is the Global Head of Public Policy at Eli Lilly & Company in Washington, D.C. Greg is also on the board of directors for the Innovation in Value Initiative (IVI), adjunct associate professor at the UNC Eshelman School of Pharmacy, and Visiting Expert at... Read More →
RG

Ryan Gough

Partner, Senior Vice President, Public Affairs, Woodberry Associates and PACH, United States
avatar for Sarah Martin

Sarah Martin

Senior Director - Global Regulatory Policy (Oncology), Eli Lilly & Co., United States
Sarah currently serves as senior director of global regulatory policy for oncology at Lilly. She previously served as senior director of science and regulatory advocacy for the Pharmaceutical Research and Manufacturers of America (PhRMA) where she led their regulatory advocacy efforts... Read More →
avatar for Julie Patterson

Julie Patterson

Senior Director of Research, National Pharmaceutical Council, United States
Julie Patterson, PharmD, PhD, is Senior Director of Research and Director of the NPC Enterprise Lab at the National Pharmaceutical Council. She designs and conducts policy-relevant research related to sustainable access to innovative biopharmaceuticals, often focusing on incentives... Read More →
avatar for Richard Xie

Richard Xie

Senior Health Economist, RA Capital Management, United States
Richard Xie has over a decade of experience in conducting rigorous economic analyses to inform health policy issues. As a Senior Health Economist at RA Capital, he collaborates with diverse stakeholders to communicate the value of pharmaceutical innovation to payers, policymakers... Read More →
Monday June 16, 2025 11:00am - 12:00pm EDT
201 Walter E. Washington Convention Center 801 Allen Y. Lew Place, NW Washington, DC 20001-3614 USA
  09: Regulatory, Forum
  • Level Intermediate
  • Keyword Payers
  • Level Intermediate
  • format csv
  • Credit Type ACPE, CME, RN
  • Feature Topics Payers
  • Tags Forum

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Tweet Share
Need help? View Support Guides
Event questions? Contact Event Planner
Powered by Sched Event Planning App
©2025 Sched • About • Privacy • Terms
Share Modal

Share this link via

Or copy link